Klaus D
Fortschr Med. 1995 Mar 10;113(7):90-6.
In an observational study lasting 6 months, 5,595 patients with essential hypertension were treated with a combination of a calcium antagonist and a diuretic, with the aim of testing the efficacy and safety of the drug. Some 63.8% oft the patients had already received anti-hypertensive treatment; 67.3% of the patients also had accompanying diseases. Treatment was begun with a single daily tablet comprising 160 mg verapamil, 50 mg triamterene and 25 mg hydrochlorothiazide (Veratide), and the dose could be reduced to one-half or increased to two daily as indicted by the response of the blood pressure.
At the end of 6 months of treatment, the overall groups showed a decrease in both systolic and diastolic blood pressure of 15.2% (26/15 mmHg). Breakdown oft the patients into various age groups revealed no differences in the results. Responder rates varied between 62.0 and 71.8%. Among patients with isolated systolic hypertension, the response rate was 66.4%. In this form of hypertension only the systolic blood pressure was lowered. During the course of treatment, 6.8% of the patients developed side effects, which were severe in 0.9% of the cases. In only 143 of the 5,595 patients did the treatment have to be broken off.
The efficacy and safety oft the combination preparation investigated have been confirmed under doctor's office conditions. The decrease in diastolic blood pressure was more marked among smokers than among non-smokers.
在一项为期6个月的观察性研究中，5595例原发性高血压患者接受了钙拮抗剂和利尿剂的联合治疗，旨在测试该药物的疗效和安全性。约63.8%的患者已经接受过抗高血压治疗；67.3%的患者还伴有其他疾病。治疗开始时每日服用一片包含160毫克维拉帕米、50毫克氨苯蝶啶和25毫克氢氯噻嗪的复方制剂（Veratide），剂量可根据血压反应减半或增至每日两片。
治疗6个月结束时，总体人群的收缩压和舒张压均下降了15.2%（26/15毫米汞柱）。将患者按不同年龄组划分后，结果没有差异。有效率在62.0%至71.8%之间。在单纯收缩期高血压患者中，有效率为66.4%。在这种高血压类型中，仅收缩压降低。在治疗过程中，6.8%的患者出现了副作用，其中0.9%的病例副作用严重。在5595例患者中，只有143例不得不中断治疗。
在诊室条件下，所研究的复方制剂的疗效和安全性已得到证实。吸烟者的舒张压下降比不吸烟者更明显。
